Glenmark Pharmaceuticals receives EIR for Ankleshwar plant

15 Mar 2017 Evaluate

Glenmark Pharmaceuticals has received the EIR (Establishment Inspection Report) for its Ankleshwar plant. The EIR is issued by the US Food and Drug Administration (USFDA) only if it finds the facility to be deemed acceptable.

The company has recently has received USFDA clearance for its Investigational New Drug (IND) application to begin a Phase 2 study of GSP 304 (tiotropium bromide) for administration by nebulization for the long term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).

Glenmark Pharmaceuticals is a global innovative pharmaceutical company with operations in more than 80 countries. It has a diverse pipeline with several compounds in various stages of clinical development primarily focused in the areas of oncology, respiratory disease, and dermatology.


Glenmark Pharma Share Price

1940.15 -25.90 (-1.32%)
17-Dec-2025 13:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1788.10
Dr. Reddys Lab 1268.80
Cipla 1494.30
Zydus Lifesciences 917.50
Lupin 2105.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×